Page 3 - Evaluate Efficacy News Today

RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2- metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus endocrine

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for...

Thirty-six abstracts underscore AbbVies commitment to advancing research to help more people living with rheumatic diseasesAdditional analysis of...

RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ i...

New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...

RINVOQ (upadacitinib) is now approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the...

A Duke Clinical Research Institute study found no difference in relief for COVID-19 symptoms for patients taking ivermectin.